查找临床试验
已按「阵发性睡眠性血红蛋白尿」检索，对应国际通用词 paroxysmal nocturnal hemoglobinuria
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 11:18，每 5 分钟自动同步Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
China
年龄 18 Years – 70 Years
Haisco Pharmaceutical Group Co., Ltd.
Study of Safety and Efficacy of MY008211A in Patients With Residual Anemia Despite Anti-C5 Antibody Treatment
China
年龄 18 Years – 75 Years
Wuhan Createrna Science and Technology Co., Ltd
A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works
Canada、Colombia、Hungary、India、Italy 等 12 国
年龄 18 Years – 不限
Regeneron Pharmaceuticals
A Phase I Clinical Trial to Evaluate CMS-D017 Following Single and Multiple Doses in Healthy Participants
China
年龄 18 Years – 55 Years
Shenzhen Kangzhe Biotechnology Co., Ltd.
A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
China
年龄 18 Years – 不限
S-INFINITY Pharmaceuticals Co., Ltd
A Phase Ib, Multicenter, Open-Label Study of Multiple-Dose EA5 in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH)
China
年龄 18 Years – 不限
Shanghai Lanyi Therapeutics Co., Ltd.
National Longitudinal Cohort of Hematological Diseases
China
年龄 不限 – 不限
Institute of Hematology & Blood Diseases Hospital, China
To Evaluate Safety, Tolerability, PK/PD & Food Effect of Single/Multiple Oral TUL321 Capsules in Healthy Participants.
China
年龄 18 Years – 45 Years
Zhuhai United Laboratories Co., Ltd.
Long-term Safety and Tolerability of MY008211A Tablets in Patients With Paroxysmal Nocturnal Hemoglobinuria
China
年龄 18 Years – 不限
Wuhan Createrna Science and Technology Co., Ltd
A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China
China
年龄 18 Years – 80 Years
Novartis Pharmaceuticals
Long-term Safety and Tolerability of HSK39297 in Patients With Paroxysmal Nocturnal Hemoglobinuria
China
年龄 18 Years – 不限
Haisco Pharmaceutical Group Co., Ltd.
Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy
China
年龄 18 Years – 75 Years
Wuhan Createrna Science and Technology Co., Ltd